Search results
Results from the WOW.Com Content Network
Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease, also known as pseudogout and pyrophosphate arthropathy, is a rheumatologic disease which is thought to be secondary to abnormal accumulation of calcium pyrophosphate dihydrate crystals within joint soft tissues. [1]
According to the American College of Rheumatology guidelines, allopurinol is the first-line medication for lowering uric acid levels. Febuxostat is another uric acid-lowering medication that may ...
Milwaukee shoulder syndrome (MSS) (apatite-associated destructive arthritis/Basic calcium phosphate (BCP) crystal arthritis/rapid destructive arthritis of the shoulder) [1] is a rare [2] rheumatological condition similar to pseudogout, associated with periarticular or intra-articular deposition of hydroxyapatite or basic calcium phosphate (BCP) crystals.
It is a component of therapy for several other conditions, including pericarditis, pulmonary fibrosis, biliary cirrhosis, various vasculitides, pseudogout, spondyloarthropathy, calcinosis, scleroderma, and amyloidosis. [33] [35] [36] Research regarding the efficacy of colchicine in many of these diseases has not been performed. [36]
Deposition of dihydrate crystals in cartilage are responsible for the severe joint pain in cases of calcium pyrophosphate deposition disease (pseudo gout) whose symptoms are similar to those of gout. [1] Ca 2 P 2 O 7 is commonly used as a mild abrasive agent in toothpastes because of its insolubility and nonreactivity toward fluoride. [2]
Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not effective or are not tolerated. [2] The drug is administered by infusion intravenously. Since October 2023, Amgen Inc. has been the marketer of pegloticase in ...
Probenecid, also sold under the brand name Probalan, is a medication that increases uric acid excretion in the urine.It is primarily used in treating gout and hyperuricemia.
Without treatment, tophi may develop on average about ten years after the onset of gout, although their first appearance can range from three to forty-two years. The development of gouty tophi can also limit joint function and cause bone destruction, leading to noticeable disabilities, especially when gout cannot successfully be treated. [ 2 ]